NEWS
September 16, 2025
KyDo Therapeutics Announces €4.45 million Seed Financing to Advance its Covalent-Allosteric Inhibitor Platform to Address Highly Unmet Medical Needs in Oncology
- KyDo secures €4.45 million Seed Funding to develop KyDo’s covalent allosteric drug discovery platform and to advance its frontrunner inhibitors towards IND-enabling studies.
- The financing round is led by I&I Bio, with a significant investment from KHAN-II, and investments from VORNvc and TU capital.
- KyDo´s lead program consists of novel covalent-allosteric inhibitors with potential to become first-in-class oncology drugs.
September 16th, 2025, Dortmund, Germany – KyDo Therapeutics GmbH (KyDo), a preclinical-stage biotechnology company committed to developing novel covalent-allosteric small molecule inhibitors with the potential to become first-in-class oncology drugs, announced today the closing of its seed financing round of €4.45 million. The financing will support the development of KyDo’s frontrunner compounds for the treatment of challenging cancer variants...